Brilliant bio pharma limited (bbpl) is a member company of 226 million us$ tgv conglomerate engaged in manufacture of veterinary biologicals and medicines. The group has diverse activities like industrial chemicals, aquaculture, salt , power, health care, hospitality industry, personal care products, veterinary biologicals and medicines. The group has to its credit the awards like “national award for safety”, “national award for environment and the “national award for r&d”.
Brilliant bio pharma limited was set up in 1988 at hyderabad to manufacture and market veterinary biologicals & medicines with the state-of-art facility. All the initial vaccine batches are tested and certified by indian veterinary research institute (ivri). The manufacturing facility is accredited with who gmp and iso 9001-2008 certification.
Mrs. Mourya boda has taken up the reigns of chairperson & managing director, brilliant bio pharma limited in 2005. She holds bachelor’s degree in law and masters in business management. She was the chairperson for young ficci ladies organization, hyderabad chapter (a division of the federation of indian chambers of commerce and industry (ficci)) during the year 2012-2013.
The r&d wing is certified by the nodal agency for certification of industrial r&d facilities in india, viz., department of science & industrial research (dsir), government of india.
The vaccines are manufactured using modern technology. The vaccines are tested and certified for their safety, sterility and potency as per various pharmacopeial standards.
Our niche products are foot and mouth disease vaccine (fmd) and rabies vaccine. The installed capacity of fmd vaccine is 100 million trivalent doses and the expansion plan for 200 million trivalent doses is in the process. The installed capacity of other bacterial vaccines and rabies vaccine is in excess of 55 million doses.
In addition to the vaccines, our product profile includes animal health products such as antibiotics and antibacterials, analgesics & antipyretics, dewormers, ecto parasiticides, feed additives and galactogogues, etc. Bbpl has the capability to formulate any animal health products (medicines) to suit the live stock requirement of the given country.
Bbpl has strong presence in domestic and international market. The products are registered and being exported to various countries in south east asia, gulf, middle east, far east, cis countries, africa and latin america.

Brilliant bio pharma limited (bbpl) is a member company of 226 million us$ tgv conglomerate engaged in manufacture of veterinary biologicals and medicines. The group has diverse activities like industrial chemicals, aquaculture, salt , power, health care, hospitality industry, personal care products, veterinary biologicals and medicines. The group has to its credit the awards like “national award for safety”, “national award for environment and the “national award for r&d”.
Brilliant bio pharma limited was set up in 1988 at hyderabad to manufacture and market veterinary biologicals & medicines with the state-of-art facility. All the initial vaccine batches are tested and certified by indian veterinary research institute (ivri). The manufacturing facility is accredited with who gmp and iso 9001-2008 certification.
Mrs. Mourya boda has taken up the reigns of chairperson & managing director, brilliant bio pharma limited in 2005. She holds bachelor’s degree in law and masters in business management. She was the chairperson for young ficci ladies organization, hyderabad chapter (a division of the federation of indian chambers of commerce and industry (ficci)) during the year 2012-2013.
The r&d wing is certified by the nodal agency for certification of industrial r&d facilities in india, viz., department of science & industrial research (dsir), government of india.
The vaccines are manufactured using modern technology. The vaccines are tested and certified for their safety, sterility and potency as per various pharmacopeial standards.
Our niche products are foot and mouth disease vaccine (fmd) and rabies vaccine. The installed capacity of fmd vaccine is 100 million trivalent doses and the expansion plan for 200 million trivalent doses is in the process. The installed capacity of other bacterial vaccines and rabies vaccine is in excess of 55 million doses.
In addition to the vaccines, our product profile includes animal health products such as antibiotics and antibacterials, analgesics & antipyretics, dewormers, ecto parasiticides, feed additives and galactogogues, etc. Bbpl has the capability to formulate any animal health products (medicines) to suit the live stock requirement of the given country.
Bbpl has strong presence in domestic and international market. The products are registered and being exported to various countries in south east asia, gulf, middle east, far east, cis countries, africa and latin america.